Scholarlink

<p>Psoriatic arthritis is an immune-mediated chronic inflammatory musculoskeletal systemic disease that affects approximately 30% of patients with psoriasis. There is increasing evidence of clinically relevant sex-specific differences in the clinical presentation, disease course, response to treatment and disease burden, with direct implications for individualized care. Women more frequently present with peripheral arthritis, higher enthesitis scores, more tender joints, greater pain and a longer symptom duration before diagnosis. Men more frequently show axial involvement, more severe skin disease and greater radiographic progression. Meta-analyses indicate a significantly poorer response to treatment with biologics in women, whereas no sex-specific differences have been observed for Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors. Women are less likely to achieve minimal disease activity and report a higher disease burden, greater fatigue and more frequent depression. Clinical implications include sex-sensitive diagnostics, closer monitoring across different indications, cardiovascular risk management and psychosocial support.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Psoriasisarthritis als systemische Erkrankung

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Nadia Ninosu,
  • Anke König,
  • Isabel Rzehak,
  • Andreas Pinter,
  • Irina Blumenstein,
  • Alica Kubesch-Grün,
  • Frank Behrens,
  • Michaela Köhm

摘要

Psoriatic arthritis is an immune-mediated chronic inflammatory musculoskeletal systemic disease that affects approximately 30% of patients with psoriasis. There is increasing evidence of clinically relevant sex-specific differences in the clinical presentation, disease course, response to treatment and disease burden, with direct implications for individualized care. Women more frequently present with peripheral arthritis, higher enthesitis scores, more tender joints, greater pain and a longer symptom duration before diagnosis. Men more frequently show axial involvement, more severe skin disease and greater radiographic progression. Meta-analyses indicate a significantly poorer response to treatment with biologics in women, whereas no sex-specific differences have been observed for Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors. Women are less likely to achieve minimal disease activity and report a higher disease burden, greater fatigue and more frequent depression. Clinical implications include sex-sensitive diagnostics, closer monitoring across different indications, cardiovascular risk management and psychosocial support.